Oritavancin Phase III Results Support FDA’s New Endpoint, Sponsor Says
This article was originally published in The Pink Sheet Daily
FDA’s new early endpoint for efficacy in ABSSSI had been criticized at the time it was released. But reporting positive results for a second Phase III study of oritavancin, The Medicines Co CEO says the agency’s ABSSSI endpoints are “appropriate” for industry.
You may also be interested in...
Company is banking on its single-dose treatment course to propel it over competitors in a crowded generic and branded space, but this may involve major changes in treatment practice, analysts say.
With two novel antibiotics approved and two more under review, 2014 is seeing the end of a long lean period for antibacterial R&D, helped by incentives like Qualified Infectious Disease Product designation. But only one candidate, Cubist’s ceftozolane/tazobactam, addresses the urgent need to target resistant Gram-negative bacteria.
Full results for Durata’s dalbavancin and The Medicine’s Co.’s oritavancin – both lipoglycopeptides – suggest the mode of administration is likely to become a key differentiating factor if the drugs are approved.